Month: April 2025

Mortgage Rates Jump Over 7% as Tariff-Driven Bond Rout Shakes Markets

Posted on by slightbourne@noblecapitalmarkets.com
Key Points:
– Mortgage rates surged to 7.1%, the highest level since February, following a sell-off in bonds.
– The bond market experienced one of its sharpest weekly moves since the early 1980s.
– Rising rates could weigh on economic growth, housing, and investor sentiment heading into Q2.

Mortgage rates jumped sharply on Friday, climbing to 7.1% for the 30-year fixed loan — their highest level since mid-February — as bond markets reeled from tariff-induced volatility. The move marked a 13-basis-point spike in a single day and capped what analysts are calling one of the most dramatic weeks in the Treasury market since 1981.

The spike followed a roller-coaster week in rates, largely driven by President Trump’s sweeping new tariffs on dozens of countries. Yields surged mid-week when the full tariff regime kicked in, then dipped after a partial rollback was announced, only to rebound on Friday. Notably, 10-year yields jumped 66 basis points from Monday’s lows, a move rarely seen outside of crisis periods.

Mortgage rates tend to track the 10-year Treasury, which helps explain the immediate impact on home financing costs. But broader bond market dislocations are now raising alarm bells across asset classes.

Matthew Graham, COO at Mortgage News Daily, described the moment as historic. “Unless your career began before 1981,” he noted, “this was likely the worst week you’ve ever seen in terms of 10-year yield volatility.” Traders and economists alike are grappling with the inflationary potential of tariffs and their longer-term implications for rates, risk, and the real economy.

Higher mortgage rates couldn’t come at a worse time for the housing market. The spring season is typically the most active for homebuying, but consumers now face steeper monthly payments just as concerns mount about job security and cost-of-living pressures. A Friday report from the University of Michigan showed consumer inflation expectations jumped from 5% to 6.7% — the highest since 1981.

In parallel, investors are also digesting early signs of an economic slowdown. GDP estimates for Q1 have been revised downward, and analysts note that consumer spending, outside of motor vehicles, was modest in March. Retail data released Friday did beat expectations, but economists caution that pre-tariff panic buying may have temporarily inflated the numbers.

For small-cap investors, the impact of higher rates is often magnified. These companies typically rely more heavily on short-term debt and floating-rate loans, making them more vulnerable to rising borrowing costs. Additionally, a potential slowdown in consumer demand could disproportionately impact the growth assumptions embedded in many small-cap valuations.

The bond market sell-off has also drawn attention to broader inflation expectations, with some economists now questioning whether the Federal Reserve will have the flexibility to cut rates as previously anticipated. If rate cuts are delayed or pared back, sectors sensitive to interest rates — from housing to tech — could feel the strain.

As the dust settles, markets will look to upcoming Fed commentary and earnings season for signals. But for now, mortgage rate watchers and equity investors alike are navigating a landscape that’s become far more uncertain in just one week.

Powell Flags Fed’s Tariff Dilemma: Inflation vs. Growth

Posted on by slightbourne@noblecapitalmarkets.com
Key Points:
– Powell warns new tariffs may fuel inflation and slow growth simultaneously.
– The Fed will wait for clearer signals before changing its policy stance.
– Pre-tariff buying and uncertain trade flows may skew short-term economic indicators.

Federal Reserve Chair Jerome Powell warned Wednesday that the central bank may face difficult trade-offs as new tariffs raise inflationary pressure while potentially slowing economic growth. Speaking before the Economic Club of Chicago, Powell said the U.S. economy could be entering a phase where the Fed’s dual mandate—price stability and maximum employment—may be in direct conflict.

“We may find ourselves in the challenging scenario in which our dual-mandate goals are in tension,” Powell said, referencing the uncertainty surrounding President Trump’s sweeping tariff policies. The White House’s new duties, which could raise prices on a wide array of imports, come just as economic data begins to show signs of cooling.

Powell noted that if inflation rises while growth slows, the Fed would have to carefully assess which goal to prioritize based on how far the economy is from each target and how long each gap is expected to last. For now, Powell indicated that the central bank would not rush into policy changes and would instead wait for “greater clarity” before adjusting interest rates.

Markets took his remarks in stride, though stocks dipped to session lows and Treasury yields edged lower. The Fed’s next move is being closely watched, especially as futures markets still price in three or four interest rate cuts by year-end. But Powell’s comments suggest the central bank is in no hurry to act amid so many moving pieces.

Trump’s tariff agenda has added complexity to the economic outlook. While tariffs are essentially taxes on imported goods and don’t always lead to sustained inflation, their scale and scope this time are different. The president’s moves have prompted businesses to front-load imports and accelerate purchases, especially in autos and manufacturing. But that activity may fade fast.

Recent retail data showed a 1.4% increase in March sales, largely due to consumers rushing to buy cars before the tariffs take hold. Powell said this kind of short-term behavior could distort near-term economic indicators, making it harder for the Fed to gauge the true health of the economy.

At the same time, Powell pointed out that survey and market-based measures of inflation expectations have begun to rise. While long-term inflation projections remain near the Fed’s 2% target, the upward drift in near-term forecasts could pose a problem if left unchecked.

The GDP outlook for the first quarter reflects this uncertainty. The Atlanta Fed, adjusting for abnormal trade flows including a jump in gold imports, now sees Q1 growth coming in flat at -0.1%. Powell acknowledged that consumer spending has cooled and imports have weighed on output.

The speech largely echoed Powell’s earlier comments this month, but with a sharper tone on trade policy risks. As the Fed walks a tightrope between inflation and growth, investors are left guessing how long it can maintain its wait-and-see posture.

Release – GeoVax Provides Update on BARDA Project NextGen and Outlines 2025 Business Momentum

Posted on by aweinsoff@channelchek.com

Research News and Market Data on GOVX

Company Reaffirms Commitment to Innovation in COVID-19, Oncology, and Biosecurity Amid Strategic Program Developments

ATLANTA, GA, April 16, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer, today addressed the termination of its Project NextGen (PNG) award by the Biomedical Advanced Research and Development Authority (BARDA), effective April 11, 2025. The Company also provided a comprehensive business update across its core programs, including the next-generation COVID-19 vaccine (GEO-CM04S1), cancer immunotherapy (Gedeptin®), Mpox/smallpox vaccine (GEO-MVA), and advanced MVA manufacturing process.

GeoVax expressed disappointment in the HHS/BARDA action but remains committed to the critical medical need addressed by GEO-CM04S1, particularly among the more than 40 million immunocompromised Americans—and over 400 million people globally—who remain inadequately protected by the current authorized COVID-19 vaccines.  Thus far, clinical data in support of GEO-CM04S1 demonstrate encouraging support of the potential of GEO-CM04S1 for providing (a) more robust immune response, (b) increased durability and (c) protective immunity for those patients with depleted immune systems inadequately responding to the current authorized COVID-19 vaccines.

The Company also noted recent public statements by HHS leadership acknowledging the potential enhanced value of multi-antigen vaccines addressing respiratory viruses.  Of special note is that GEO-CM04S1 was the only multi-antigen/polyvalent COVID-19 vaccine candidate selected under the PNG initiative.

“While the recent HHS/BARDA Stop Work Order action was disappointing and surprising, our commitment to protecting vulnerable populations remains unchanged, and our clinical momentum is strong in support of our ongoing Phase 2 GEO-CM04S1 programs,” said David Dodd, Chairman and CEO of GeoVax.

Continued Progress Across a Catalyst-Rich Pipeline

GEO-CM04S1: Advancing to Meet Unmet COVID-19 Needs

GEO-CM04S1 continues to demonstrate potential as both a primary and booster vaccine, especially in immunocompromised patients. Key milestones anticipated during 2025 include:

  • Healthy Adult Booster Trial – Enrollment is complete; data readout expected in H1 2025.
  • CLL Patient Study (Immunocompromised patient study) – Ongoing enrollment; interim results resulted in continuation of the GEO-CM04S1 arm, whereas the Data Safety Review Board recommended early termination of the mRNA arm, which was subsequently implemented.
  • Stem Cell Transplant/CAR-T Trial (Immunocompromised patient study) – Enrollment and evaluation continue among hematological patients receiving stem cell transplantation or CAR-T therapy, comparing GEO-CM04S1 to mRNA COVID-19 vaccines.

GEO-CM04S1 is a multi-antigen COVID-19 vaccine, utilizing a synthetic-MVA platform, expressing both S and N antigens, offering the potential for broader, more durable protection than current mRNA vaccines.

Gedeptin®: Advancing into Phase 2 in Solid Tumors

GeoVax’s oncology program, utilizing the Gedeptin® technology, is planned to progress to a Phase 2 trial in combination with an immune checkpoint inhibitor for first recurrent head and neck cancer. Gedeptin has received Orphan Drug designation for use among advanced head & neck cancer patients.  The Gedeptin technology provides potential for expansion into other solid tumors including triple-negative breast cancer, melanoma, and soft tissue sarcoma.

GEO-MVA: Addressing Biosecurity and Global Vaccine Equity

GeoVax anticipates initiating clinical trials in 2025 for GEO-MVA, its Mpox/smallpox vaccine candidate. The Company has successfully produced cGMP clinical product and is focused on completing the vaccine vialing in support of initiating clinical evaluation during H2 2025.  GEO-MVA positions GeoVax to offer a U.S.-developed alternative to foreign-sourced vaccines amid rising global biosecurity threats and constrained supply.

Advanced Manufacturing: Scaling MVA for Global Reach

GeoVax is advancing continuous cell line manufacturing for MVA-based vaccines, offering a path to scalable, cost-effective production—including localized manufacturing for low- and middle-income countries. This innovation addresses critical gaps in vaccine self-sufficiency and supply resilience.

Outlook for 2025

Despite the PNG award termination, GeoVax anticipates a milestone-rich 2025 across its portfolio. The Company will continue to engage with government and industry partners, pursue clinical trial completions, and drive innovation through expanded AI integration to optimize development, trial operations, and manufacturing efficiency.

“Our scientific foundation is strong and our strategy is clear,” added Dodd. “GeoVax remains committed to delivering transformative solutions for unmet medical needs in infectious disease and cancer. We’re advancing with purpose and fully prepared to deliver on the promise of our development program.”

For further details on GeoVax’s programs and progress, visit www.geovax.com.

About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company’s lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. The Company is also developing GEO-MVA, a vaccine targeting Mpox and smallpox. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com.

Forward-Looking Statements

This release contains forward-looking statements regarding GeoVax’s business plans. The words “believe,” “look forward to,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax’s immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax’s viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax’s immuno-oncology products and preventative vaccines will be safe for human use, GeoVax’s vaccines will effectively prevent targeted infections in humans, GeoVax’s immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax’s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.

Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. 

Company Contact:                 

info@geovax.com                   

678-384-7220                          

Investor Relations Contact:

geovax@precisionaq.com

212-698-8696

Gold Hits Record Highs, Becomes Wall Street’s Hottest Trade in 2025

Posted on by slightbourne@noblecapitalmarkets.com
Key Points:
– Gold has overtaken the “Magnificent Seven” tech stocks as the most crowded trade on Wall Street.
– Gold futures have hit a record $3,334 per ounce, rising over 27% year to date.
– Shifting sentiment may benefit small-cap gold miners as capital rotates into safe-haven assets.

Gold is having its moment. In a year marked by volatility, uncertainty, and waning confidence in traditional tech plays, the precious metal has surged to all-time highs, overtaking the once-dominant “Magnificent Seven” tech stocks as Wall Street’s most crowded trade.

Gold futures (GC=F) soared to a new record of $3,334 per ounce this week, pushing year-to-date gains past 27%. This run-up is more than just a short-term spike — it marks a dramatic shift in sentiment from the high-growth, high-risk appetite that dominated the last bull cycle to a focus on stability, safety, and long-term value preservation. According to the latest Bank of America fund managers survey, nearly half (49%) of respondents identified “long gold” as the most crowded trade right now — the first time in two years that gold, not tech, has held that title.

Compare that with the once-revered Magnificent Seven — Apple, Microsoft, Alphabet, Amazon, Meta, Tesla, and Nvidia — which have seen steep drawdowns in 2025. Tesla leads the slump with a 38% drop, while Apple and Nvidia have both tumbled 21%. Regulatory headwinds, rising costs, and tariff uncertainty have weighed on investor sentiment across the sector, leaving room for gold to steal the spotlight.

The reasons behind gold’s surge are multifaceted. First, central bank demand remains at record levels, with nations diversifying away from dollar-denominated assets. Second, inflows into gold-backed ETFs have risen as both institutional and retail investors look for shelter amid geopolitical instability and a weakening US dollar. The backdrop of rising trade tensions — particularly the escalating tariff battle between the US and China — has further fueled safe-haven demand.

More than just a hedge against inflation, gold is now seen as a vote of no confidence in the current trajectory of US economic policy. The Bank of America survey found that 73% of fund managers believe “US exceptionalism” has peaked — a notable shift that helps explain the flow of capital out of American equities and into alternative stores of value like gold.

While retail investors often focus on the headline gold price, it’s worth noting the broader implications for capital markets — including small and micro-cap stocks. With capital rotating out of mega-cap tech and into inflation-resistant assets, small-cap gold miners and exploration companies could stand to benefit. These stocks, often overlooked in favor of more liquid plays, may now see increased institutional attention as gold continues to climb.

Investor sentiment is clearly shifting. Wall Street analysts have begun raising their price targets for gold, and some 42% of fund managers now say it will be the best-performing asset of 2025 — up from just 23% last month. As confidence in traditional market leaders continues to erode, gold’s appeal looks less like a trade and more like a trend.

Release – 1-800-FLOWERS.COM, Inc. to Release its Fiscal 2025 Third Quarter Results on Thursday, May 8, 2025

Posted on by aweinsoff@channelchek.com

Research News and Market Data on FLWS

Apr 16, 2025

JERICHO, N.Y.–(BUSINESS WIRE)– 1-800-FLOWERS.COM, Inc. (NASDAQ: FLWS) (the “Company”),a leading provider of gifts designed to help inspire customers to give more, connect more, and build more and better relationships, today announced that the Company will release financial results for its fiscal 2025 third quarter on Thursday, May 8,2025. The press release will be issued after the market close and will be followed by a conference call with members of senior management at 4:30 p.m. (ET).

The conference call will be available via live webcast from the Investors section of the Company’s website at www.1800flowersinc.com/investors. A recording of the call will be posted on the website within two hours of the call’s completion. A telephonic replay of the call can be accessed beginning at 7:00 p.m. (ET) on May 8, 2025, through May 15, 2025, at: (US) 1-877-344-7529; (Canada) 855-669-9658; (International) 1-412-317-0088; enter conference ID: #4626916.

Special Note Regarding Forward-Looking Statements:

Some of the statements contained in the Company’s scheduled Thursday, May 8, 2025, press release and conference call regarding its results for its fiscal 2025 third quarter, other than statements of historical fact, may be forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the applicable statements. For a more detailed description of these and other risk factors, please refer to the Company’s SEC filings including its Annual Reports and Forms 10K and 10Q available at the Investor Relations section of the Company’s website at 1800flowersinc.com. The Company expressly disclaims any intent or obligation to update any of the forward-looking statements made in the scheduled conference call and any recordings thereof, or in any of its SEC filings, except as may be otherwise stated by the Company.

About 1-800-FLOWERS.COM, Inc.

1-800-FLOWERS.COM, Inc. is a leading provider of gifts designed to help inspire customers to give more, connect more, and build more and better relationships. The Company’s e-commerce business platform features an all-star family of brands, including: 1-800-Flowers.com®, 1-800-Baskets.com®, Cheryl’s Cookies®, Harry & David®, PersonalizationMall.com®, Shari’s Berries®, FruitBouquets.com®, Things Remembered®, Moose Munch®, The Popcorn Factory®, Wolferman’s Bakery®, Vital Choice®, Simply Chocolate® and Scharffen Berger®. Through the Celebrations Passport® loyalty program, which provides members with free standard shipping and no service charge on eligible products across our portfolio of brands, 1-800-FLOWERS.COM, Inc. strives to deepen relationships with customers. The Company also operates BloomNet®, an international floral and gift industry service provider offering a broad-range of products and services designed to help members grow their businesses profitably; Napco℠, a resource for floral gifts and seasonal décor; DesignPac Gifts, LLC, a manufacturer of gift baskets and towers; Alice’s Table®, a lifestyle business offering fully digital livestreaming and on demand floral, culinary and other experiences to guests across the country; and Card Isle®, an e-commerce greeting card service. 1-800-FLOWERS.COM, Inc. was recognized among America’s Most Trustworthy Companies by Newsweek. 1-800-FLOWERS.COM, Inc. was also recognized as one of America’s Most Admired Workplaces for 2025 by Newsweek and was named to the Fortune 1000 list in 2022. Shares in 1-800-FLOWERS.COM, Inc. are traded on the NASDAQ Global Select Market, ticker symbol: FLWS. For more information, visit 1800flowersinc.com.

FLWS-COMP
FLWS-FN

Investor Contact:

Andy Milevoj

amilevoj@1800flowers.com

Media Contact:

Cherie Gallarello

cgallarello@1800flowers.com

Source: 1-800-FLOWERS.COM, Inc.

Release – Comstock Metals and RWE Enter Strategic Solar Recycling Partnership

Posted on by aweinsoff@channelchek.com

Research News and Market Data on LODE

Virginia City, Nevada, April 16, 2025 – Comstock Inc. (NYSE American: LODE) announced today that its subsidiary, Comstock Metals LLC (“Comstock Metals”), a pioneer in sustainable, zero-landfill solar panel recycling has entered into a Master Services Agreement (MSA) with RWE Clean Energy, the U.S. subsidiary of leading global energy company, RWE.

Comstock Metals will provide RWE with recycling, decommissioning, and logistics services for their expansive U.S. solar installations ensuring a zero-landfill solution for 100% of the recovered solar panel materials.

Under the terms of this new agreement, Comstock Metals will serve as a preferred, strategic partner for the recycling, disposal, and decommissioning services for RWE’s solar installations. These projects will include the recycling of solar panels and related equipment, logistics management, eco-friendly disposal practices, and the safe transportation of materials. “This partnership underscores our shared commitment to sustainability and innovation,” stated Dr. Fortunato Villamagna, President of Comstock Metals. “RWE has consistently showcased exceptional commitment to their mission of providing renewable energy solutions by leading the adoption of solar energy and reducing carbon emissions. Comstock Metals complements RWE’s efforts as a trusted provider in the renewable energy market, ensuring environmentally conscious recycling of the solar panels and their components.”

This agreement represents a continuation and expansion of the successful collaboration between the dedicated teams of Comstock Metals and RWE on multiple projects throughout Nevada and California. Comstock Metals has already successfully coordinated the decommissioning, transportation, and recycling of more than 4 million pounds of end-of-life solar materials for RWE, with much more anticipated as demand for responsible recycling grows.

“Comstock Metals continues to systemically identify and close critical gaps in the nascent solar panel recycling sector, creating new capabilities and long-term service opportunities for both the company and the entire supply chain,” said Comstock Inc.’s Executive Chairman and CEO, Corrado De Gasperis. “With these rapidly expanding industry partnerships, we are creating unique, sustainable, and full-service solutions for the world’s most renowned renewable energy companies.”

About RWE in the U.S.

Through its subsidiary RWE Clean Energy, RWE is the third largest renewable energy company in the United States, with a presence in most U.S. states from coast to coast. RWE’s team of about 2,000 employees in the U.S. stands ready to help meet the nation’s growing energy needs. With its homegrown and fastest-to-market product, RWE supports the goal of American Energy dominance and independence. To that end, RWE Clean Energy is committed to increasing its already strong asset base of over 10 gigawatts of operating wind, solar and battery projects, focusing on providing high-quality jobs. RWE invests in local and rural communities while strengthening domestic manufacturing supporting the renaissance of American industry. This is complemented by RWE’s energy trading business. RWE is also a major offtaker of American liquified natural gas (LNG). To learn more, please visit RWE Clean Energy website.

As an energy company with a successful history spanning more than 125 years, RWE has an extensive knowledge of the energy markets and an excellent expertise in all major power generation and storage technologies, from nuclear, coal and gas to hydro, batteries, wind and solar.

About Comstock Metals

Comstock Metals is a leading, Nevada-based, zero-landfill recycling solution that specializes in the environmentally responsible recycling of solar panels and related renewable energy infrastructure and equipment. Comstock’s unique thermal delaminating processes, ongoing material innovations, and sustainable practices differentiates its recycling leadership and strengthens the supply chain of domestically manufactured electrification products. www.comstockmetals.com

About Comstock Inc.

Comstock Inc. (NYSE: LODE) innovates and commercializes technologies that are deployable across entire industries to contribute to energy abundance by efficiently extracting and converting under-utilized natural resources, such as waste and other forms of woody biomass into renewable fuels, and end-of-life electronics into recovered electrification metals. Comstock’s innovations group is also developing and using artificial intelligence technologies for advanced materials development and mineral discovery for sustainable mining. To learn more, please visit www.comstock.inc.

Comstock Social Media Policy

Comstock Inc. has used, and intends to continue using, its investor relations link and main website at www.comstock.inc in addition to its X.com, LinkedIn and YouTube accounts, as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

Contacts

For investor inquiries:
William McCarthy, Chief Operating Officer
Tel (775) 413-6222
ir@comstockinc.com

For media inquiries:
Tracy Saville, Director of Marketing
Tel (775) 847-7573
media@comstockinc.com

Forward-Looking Statements 

This press release and any related calls or discussions may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, are forward-looking statements. The words “believe,” “expect,” “anticipate,” “estimate,” “project,” “plan,” “should,” “intend,” “may,” “will,” “would,” “potential” and similar expressions identify forward-looking statements but are not the exclusive means of doing so. Forward-looking statements include statements about matters such as: future market conditions; future explorations or acquisitions; future changes in our research, development and exploration activities; future financial, natural, and social gains; future prices and sales of, and demand for, our products and services; land entitlements and uses; permits; production capacity and operations; operating and overhead costs; future capital expenditures and their impact on us; operational and management changes (including changes in the Board of Directors); changes in business strategies, planning and tactics; future employment and contributions of personnel, including consultants; future land and asset sales; investments, acquisitions, joint ventures, strategic alliances, business combinations, operational, tax, financial and restructuring initiatives, including the nature, timing and accounting for restructuring charges, derivative assets and liabilities and the impact thereof; contingencies; litigation, administrative or arbitration proceedings; environmental compliance and changes in the regulatory environment; offerings, limitations on sales or offering of equity or debt securities, including asset sales and associated costs; business opportunities, growth rates, future working capital, needs, revenues, variable costs, throughput rates, operating expenses, debt levels, cash flows, margins, taxes and earnings. These statements are based on assumptions and assessments made by our management in light of their experience and their perception of historical and current trends, current conditions, possible future developments and other factors they believe to be appropriate. Forward-looking statements are not guarantees, representations or warranties and are subject to risks and uncertainties, many of which are unforeseeable and beyond our control and could cause actual results, developments, and business decisions to differ materially from those contemplated by such forward-looking statements. Some of those risks and uncertainties include the risk factors set forth in our filings with the SEC and the following: adverse effects of climate changes or natural disasters; adverse effects of global or regional pandemic disease spread or other crises; global economic and capital market uncertainties; the speculative nature of gold or mineral exploration, and lithium, nickel and cobalt recycling, including risks of diminishing quantities or grades of qualified resources; operational or technical difficulties in connection with exploration, metal recycling, processing or mining activities; costs, hazards and uncertainties associated with precious and other metal based activities, including environmentally friendly and economically enhancing clean mining and processing technologies, precious metal exploration, resource development, economic feasibility assessment and cash generating mineral production; costs, hazards and uncertainties associated with metal recycling, processing or mining activities; contests over our title to properties; potential dilution to our stockholders from our stock issuances, recapitalization and balance sheet restructuring activities; potential inability to comply with applicable government regulations or law; adoption of or changes in legislation or regulations adversely affecting our businesses; permitting constraints or delays; challenges to, or potential inability to, achieve the benefits of business opportunities that may be presented to, or pursued by, us, including those involving battery technology and efficacy, quantum computing and generative artificial intelligence supported advanced materials development, development of cellulosic technology in bio-fuels and related material production; commercialization of cellulosic technology in bio-fuels and generative artificial intelligence development services; ability to successfully identify, finance, complete and integrate acquisitions, joint ventures, strategic alliances, business combinations, asset sales, and investments that we may be party to in the future; changes in the United States or other monetary or fiscal policies or regulations; interruptions in our production capabilities due to capital constraints; equipment failures; fluctuation of prices for gold or certain other commodities (such as silver, zinc, lithium, nickel, cobalt, cyanide, water, diesel, gasoline and alternative fuels and electricity); changes in generally accepted accounting principles; adverse effects of war, mass shooting, terrorism and geopolitical events; potential inability to implement our business strategies; potential inability to grow revenues; potential inability to attract and retain key personnel; interruptions in delivery of critical supplies, equipment and raw materials due to credit or other limitations imposed by vendors; assertion of claims, lawsuits and proceedings against us; potential inability to satisfy debt and lease obligations; potential inability to maintain an effective system of internal controls over financial reporting; potential inability or failure to timely file periodic reports with the Securities and Exchange Commission; potential inability to list our securities on any securities exchange or market or maintain the listing of our securities; and work stoppages or other labor difficulties. Occurrence of such events or circumstances could have a material adverse effect on our business, financial condition, results of operations or cash flows, or the market price of our securities. All subsequent written and oral forward-looking statements by or attributable to us or persons acting on our behalf are expressly qualified in their entirety by these factors. Except as may be required by securities or other law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Neither this press release nor any related calls or discussions constitutes an offer to sell, the solicitation of an offer to buy or a recommendation with respect to any securities of the Company, the fund, or any other issuer.

QuoteMedia Inc. (QMCI) – Not Getting Revenue Traction

Posted on by cpereira@noblefcm.com


Wednesday, April 16, 2025

QuoteMedia is a leading software developer and cloud-based syndicator of financial market information and streaming financial data solutions to media, corporations, online brokerages, and financial services companies. The Company licenses interactive stock research tools such as streaming real-time quotes, market research, news, charting, option chains, filings, corporate financials, insider reports, market indices, portfolio management systems, and data feeds. QuoteMedia provides industry leading market data solutions and financial services for companies such as the Nasdaq Stock Exchange, TMX Group (TSX Stock Exchange), Canadian Securities Exchange (CSE), London Stock Exchange Group, FIS, U.S. Bank, Broadridge Financial Systems, JPMorgan Chase, CI Financial, Canaccord Genuity Corp., Hilltop Securities, HD Vest, Stockhouse, Zacks Investment Research, General Electric, Boeing, Bombardier, Telus International, Business Wire, PR Newswire, FolioFN, Regal Securities, ChoiceTrade, Cetera Financial Group, Dynamic Trend, Inc., Qtrade Financial, CNW Group, IA Private Wealth, Ally Invest, Inc., Suncor, Virtual Brokers, Leede Jones Gable, Firstrade Securities, Charles Schwab, First Financial, Cirano, Equisolve, Stock-Trak, Mergent, Cision, Day Trade Dash and others. Quotestream®, QModTM and Quotestream ConnectTM are trademarks of QuoteMedia. For more information, please visit www.quotemedia.com.

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

In-line results. The company reported Q4 revenue of $4.7 million and adj. EBITDA of $0.2 million, both of which were largely in line with our estimates of $4.6 million and $0.3 million, respectively, as illustrated in Figure #1 Q4 Results. Notably, both revenue and adj. EBITDA for 2024 decreased from the prior year, which was largely attributed to key clients facing difficulties during the year and reducing spending or discontinuing services entirely.

A difficult year. During the company’s Q3 earnings call, management highlighted the loss of a large client and indicated that some of its other clients are facing financial hardship, even though management indicated that there was a strong pipeline, albeit with a long ramp-up period. As such, the year-end results were largely expected to be lackluster. 


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Longevity Health Merges with 20/20 BioLabs in Bid to Redefine Healthy Aging

Posted on by slightbourne@noblecapitalmarkets.com
Key Points:
– Longevity Health and 20/20 BioLabs to merge, forming a $99M company focused on diagnostics and healthy aging.
– 2025 revenue expected to double post-merger, driven by cross-sell opportunities and product synergies.
– Combined firm targets expanding into MedSpas, retail, and clinical settings, reflecting a hybrid approach to wellness and diagnostics.

Longevity Health Holdings (Nasdaq: XAGE) is doubling down on its ambition to lead the healthy aging and diagnostics market with the announcement of a strategic all-stock merger with 20/20 BioLabs, a provider of cutting-edge diagnostic tests for early cancer detection and chronic disease risk management. The deal, which is expected to close in Q3 2025, marks another step in Longevity’s pivot toward becoming a vertically integrated longevity-focused healthcare platform.

The merger comes just months after Longevity’s acquisition of Elevai Skincare and follows the company’s March 2025 announcement outlining a broader strategy to combine diagnostics, bio-aesthetics, and nutrition under the unifying theme “Healthy Aging, Inside and Out™.” With 20/20’s technology and distribution capabilities, Longevity is adding a diagnostics engine to its growing wellness infrastructure and positioning itself as a unique player at the intersection of science, skincare, and preventative healthcare.

Under the terms of the agreement, 20/20 shareholders will own approximately 50.1% of the combined company, with Longevity shareholders retaining 49.9%—a sign of parity and the significance of what 20/20 brings to the table. The merged company will continue to trade under the ticker “XAGE” on the Nasdaq.

Founded in Gaithersburg, Maryland, 20/20 operates a CLIA-licensed and CAP-accredited laboratory and has developed OneTest™, a multi-cancer early detection (MCED) blood test capable of identifying over a dozen tumor types for under $200. The company has already integrated its tests into wellness protocols for firefighters and military veterans and is preparing to launch a new “longevity test” this spring that evaluates inflammatory markers tied to aging and disease risk.

Financially, the merger is set to double Longevity’s expected revenue for fiscal year 2025 from $3–4 million to $7–8 million and deliver at least $1 million in operational synergies. The combined company’s equity valuation is pegged at $99 million, offering a promising growth profile in a market that increasingly values integrated health solutions.

For small-cap investors, the deal highlights an emerging investment theme: convergence in wellness, biotech, and diagnostics. Longevity is carving out a niche in a crowded but high-potential market by integrating scientific, consumer-facing products with medical-grade diagnostics. This cross-disciplinary approach could make it more resilient than standalone players focused solely on aesthetics or lab testing.

Beyond the numbers, Longevity plans to offer 20/20’s tests through its network of physicians to inform more personalized bio-aesthetic treatment plans. Conversely, 20/20 will gain access to Longevity’s customer base—including thousands of firefighters—to introduce its diagnostics in new environments, including MedSpas and retail.

Leadership will be shared post-merger. Longevity’s Rajiv Shukla will remain Chairman, while 20/20’s Jonathan Cohen will step in as CEO, underscoring a collaborative transition.

As Longevity eyes further acquisitions, this deal positions it as a unique micro-cap consolidator in the rapidly evolving healthy aging space. Investors should watch closely as the company scales up from niche science to potentially mass-market longevity solutions.

Small-Caps: Are Investors Throwing Out the Baby with the Bathwater?

Posted on by slightbourne@noblecapitalmarkets.com

The small-cap sector has taken it on the chin in recent months, with widespread fear and macro uncertainty fueling a broad selloff that’s left many fundamentally solid companies trading at multi-year lows. While this environment has caused plenty of investors to retreat to the safety of larger, more liquid names, it’s also creating potential opportunities for those with a longer-term mindset.

The Russell 2000, which tracks small-cap performance, has declined steeply this year—reflecting the risk-off tone in the market. But with this pullback comes the chance to scoop up high-quality businesses at a steep discount to their intrinsic value. Historically, moments of panic often set the stage for future gains, especially in the small-cap space where sentiment tends to swing more dramatically. Right now, the indiscriminate nature of the selling has created an environment where price and value have diverged, opening the door for patient investors to build positions in companies that have been unfairly punished.

One such example is NN, Inc. (NNBR), a precision manufacturing company that operates in sectors like automotive and medical, offering highly engineered solutions. Back in December, the stock was trading around $4, but it has since dropped to roughly $1.73. While that kind of decline might suggest something is seriously broken, the business itself continues to pursue operational improvements and efficiency gains. The company has made progress in reducing debt and focusing its portfolio, and though headwinds remain, the market appears to be pricing in a worst-case scenario. For investors who believe in industrial recovery and the power of long-term restructuring, NNBR may represent deep value.

Another name that’s been dragged down in the recent slide is 1-800-Flowers.com (FLWS). In December, this online retailer was trading near $9 per share. Fast forward to today, and it’s sitting around $5.20. Despite the decline, the underlying business remains healthy. The company continues to benefit from strong seasonal demand, and its ability to cross-sell across its various gifting platforms—ranging from floral to gourmet foods—gives it a unique edge in the e-commerce space. As consumer habits shift further toward online shopping and direct-to-door services, 1-800-Flowers stands to be a long-term winner. The current pullback may have more to do with general retail fatigue and market fear than any material weakness in the business itself.

Conduent (CNDT) rounds out the list, trading at just $2 after closing last year around $4.39. Specializing in business process outsourcing and digital workflow solutions for both government and commercial clients, Conduent has a significant contract base and recurring revenue streams that provide a level of stability often overlooked in smaller tech-enabled firms. While the company has faced its share of execution challenges, it continues to win contracts and drive efficiency through restructuring efforts. If management continues to make progress and market sentiment shifts even slightly, CNDT could see meaningful upside from these levels.

In volatile times like these, it’s easy to let fear cloud judgment. But for investors who can see past short-term noise, the current small-cap selloff may offer a rare opportunity to buy good companies on sale.

Release – Saga Communications, Inc. Announces Date and Time of 1st Quarter Earnings Release and Conference Call

Posted on by aweinsoff@channelchek.com

Research News and Market Data on SGA

April 14, 2025 16:05 ET 

GROSSE POINTE FARMS, Mich., April 14, 2025 (GLOBE NEWSWIRE) — Saga Communications, Inc. (Nasdaq: SGA) announced today that it will release its 1st Quarter 2025 results at 9:00 a.m. EDT on Thursday, May 8, 2025. The company will be holding a conference call on the same date at 11:00 a.m. EDT. The dial-in numbers are as follows:

Domestic and International Dial-in Number: (973) 528-0008
Conference Entry Code: 530273

The Company requests that all parties that have a question that they would like to submit to the Company to please email the inquiry by 10:00 a.m. EDT on May 8, 2025, to SagaIR@sagacom.com. The Company will discuss, during the limited period of the conference call, those inquiries it deems of general relevance and interest. Only inquiries made in compliance with the foregoing will be discussed during the call.

Saga’s earnings release will contain certain non-GAAP financial measures including station operating income, trailing 12-month consolidated EBITDA, and same station financial information. A reconciliation of all non-GAAP financial measures to the most directly comparable GAAP measures will be provided in the earnings release.

Saga is a media company whose business is devoted to acquiring, developing, and operating broadcast properties with a focus on providing opportunities complimentary to our core radio business including digital, e-commerce, local on-line news services and non-traditional revenue initiatives.  Saga owns or operates broadcast properties in 28 markets, including 82 FM and 32 AM radio stations and 79 metro signals. For additional information, contact us at (313) 886-7070 or visit our website at www.sagacom.com.

Contact:
Samuel D. Bush
(313) 886-7070

Release – Alliance Resource Partners, L.P. Announces Jesse M. Parrish Will Serve as Senior Vice President of Alliance Coal, LLC

Posted on by aweinsoff@channelchek.com

Research News and Market Data on ARLP

Apr 14, 2025 3:36 PM Eastern Daylight Time

TULSA, Okla.–(BUSINESS WIRE)–Alliance Resource Partners, L.P. (NASDAQ: ARLP) today announces that Jesse M. Parrish will join Alliance Coal, LLC (“Alliance Coal”) as its Senior Vice President – Operations where he will be responsible for assisting with the management of our coal operations. Mr. Parrish previously served as Chief Executive Officer of Blackhawk Mining, LLC (“Blackhawk”), which produces metallurgical coal at eight mining complexes across southern West Virginia and eastern Kentucky and employs approximately 2,000 people.

“I am pleased to welcome Jesse to ARLP,” said Joseph W. Craft III, Chairman, President and Chief Executive Officer. “Jesse’s strong leadership skills, experience and expertise in the coal industry will be a valuable addition to the Alliance Coal management team as we continue to provide our customers with reliable baseload fuel to meet the significant growth in U.S. electricity demand from data centers and on-shoring of manufacturing. I look forward to working closely with him to deliver attractive returns to our unitholders.”

Prior to serving as Chief Executive Officer, Mr. Parrish held various other positions over his long career at Blackhawk, including President, Chief Financial Officer, Vice President and Director of Strategic Planning and Corporate Communications at Blackhawk. Prior to joining Blackhawk, Jesse practiced law at Bingham Greenebaum Doll LLP, where he focused on coal-related financings, mergers and acquisitions, and environmental matters. Mr. Parrish is a graduate of the University of Kentucky with a Bachelor of Business Administration in Finance and a Juris Doctor. Parrish has previously served as the chairman for the West Virginia Coal Association and the Kentucky Coal Association and is a trustee for the Energy and Mineral Law Foundation.

About Alliance Resource Partners, L.P.

ARLP is a diversified energy company that is currently the second largest coal producer in the eastern United States, supplying reliable, affordable energy domestically and internationally to major utilities, metallurgical and industrial users. ARLP also generates operating and royalty income from mineral interests it owns in strategic coal and oil & gas producing regions in the United States. In addition, ARLP is positioning itself as a reliable energy partner for the future by pursuing opportunities that support the growth and development of energy and related infrastructure.

News, unit prices and additional information about ARLP, including filings with the Securities and Exchange Commission (“SEC”), are available at www.arlp.com. For more information, contact the investor relations department of ARLP at (918) 295-7673 or via e-mail at investorrelations@arlp.com.

Contacts

Investor Relations Contact
Cary P. Marshall
Senior Vice President and Chief Financial Officer
(918) 295-7673
investorrelations@arlp.com

Release – Townsquare Announces Conference Call to Discuss First Quarter 2025 Results

Posted on by aweinsoff@channelchek.com

Research News and Market Data on TSQ

PURCHASE, N.Y., April 14, 2025 (GLOBE NEWSWIRE) — Townsquare Media, Inc. (NYSE: TSQ) (“Townsquare” or the “Company”) announced today that it will release first quarter 2025 financial results before the market opens on Thursday, May 8, 2025. The Company will host a conference call to discuss certain first quarter 2025 financial results on Thursday, May 8, 2025 at 8:00 a.m. Eastern Time.

The conference call dial-in number is 1-800-717-1738 (U.S. & Canada) or 1-646-307-1865 (International) and the conference ID is “Townsquare.” A live webcast of the conference call as well as the press release disclosing the Company’s results will be available on the investor relations page of the Company’s website at www.townsquaremedia.com.

A telephone replay of the conference call will be available through May 15, 2025. To access the replay, please dial 1-844-512-2921 (U.S. & Canada) or 1-412-317-6671 (International) and enter confirmation code 1134601. A web-based archive of the conference call will also be available on the investor relations page of the Company’s website.

About Townsquare Media, Inc.
Townsquare is a community-focused digital and broadcast media and digital marketing solutions company principally focused outside the top 50 markets in the U.S. Townsquare Ignite, our robust digital advertising division, specializes in helping businesses of all sizes connect with their target audience through data-driven, results based strategies, by utilizing a) our proprietary digital programmatic advertising technology stack with an in-house demand and data management platform and b) our owned and operated portfolio of more than 400 local news and entertainment websites and mobile apps along with a network of leading national music and entertainment brands, collecting valuable first party data. Townsquare Interactive, our subscription digital marketing services business, partners with SMBs to help manage their digital presence by providing a SAAS business management platform, website design, creation and hosting, search engine optimization and other digital services. And through our portfolio of local radio stations strategically situated outside the Top 50 markets in the United States, we provide effective advertising solutions for our clients and relevant local content for our audiences. For more information, please visit www.townsquaremedia.com, www.townsquareinteractive.com, and www.townsquareignite.com.

Investor Relations
Claire Yenicay
(203) 900-5555
investors@townsquaremedia.com

GeoVax Labs (GOVX) – Stop Work Order Received For Project NextGen Trial – No Impact On Other Programs

Posted on by cpereira@noblefcm.com


Tuesday, April 15, 2025

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel therapies and vaccines for solid tumor cancers and many of the world’s most threatening infectious diseases. The company’s lead program in oncology is a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, presently in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax’s lead infectious disease candidate is GEO-CM04S1, a next-generation COVID-19 vaccine targeting high-risk immunocompromised patient populations. Currently in three Phase 2 clinical trials, GEO-CM04S1 is being evaluated as a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, and as a booster vaccine in patients with chronic lymphocytic leukemia (CLL). In addition, GEO-CM04S1 is in a Phase 2 clinical trial evaluating the vaccine as a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. GeoVax has a leadership team who have driven significant value creation across multiple life science companies over the past several decades.

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

GeoVax Has Received A Stop Work Order For The Phase 2b Trial. GeoVax has received a Stop Work order for its BARDA-sponsored Phase 2b trial testing of CM04S1 for COVID-19. We have known about other Project NextGen-funded COVID-19 trials that were halted, but hoped the CM04S1 program would continue.

Background On The Phase 2 Trial. In June 2024, BARDA (an office within HHS) selected CM04S1 for a Phase 2b trial to test efficacy, immunogenicity, and safety for protection against COVID-19 as part of Project NexGen. We had expected GeoVax to receive about $25 million for its work on trial design and supplies to be received over several years. During FY2024, GeoVax received payments of $4.0 million.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.